摘要
目的探讨瑞舒伐他汀钙对冠脉造影患者肾组织的保护作用。方法 2012年8月到2015年1月选择急性冠脉综合征患者120例,根据随机数字表法分为治疗组与对照组各60例。两组都给予造影介入治疗,治疗组行介入术前3 d给予瑞舒伐他汀20 mg强化治疗,对照组给予瑞舒伐他汀10 mg强化治疗。比较两组造影剂肾病发生情况,观察术前、术后血肌酐、尿素氮和尿微量白蛋白含量。结果治疗组的造影剂肾病发生率为1.7%,对照组为10.0%,治疗组造影剂肾病发生率明显低于对照组(P<0.05)。两组术前血肌酐和尿素氮含量对比差异无统计学意义(P>0.05),治疗组术后第 1 天与术后第 3 天的血肌酐和尿素氮含量明显低于对照组( P < 0. 05) ,与术前对比差异无统计学意义( P > 0. 05) 。治疗组术前、术后第 1 天与术后第 3 天的尿微量白蛋白含量分别为 0. 89 ± 0. 24 mg /L、1. 01 ± 0. 21 mg /L和 0. 90 ± 0. 31 mg /L; 而对照组分别为 0. 91 ± 0. 13 mg /L、1. 29 ± 0. 28 mg /L 和 1. 26 ± 0. 32 mg /L,治疗组术后第 1 天与术后第 3 天的尿微量白蛋白含量明显低于对照组( P < 0. 05) 。结论大剂量瑞舒伐他汀钙在冠脉造影患者中的应用能减少造影剂肾病的发生,对血尿素氮与肌酐水平都无明显影响,具有减轻肾脏损伤的作用,从而有效发挥肾组织保护作用。治疗组术后第1天与术后第3天的血肌酐和尿素氮含量明显低于对照组(P<0.05),与术前对比差异无统计学意义(P>0.05)。治疗组术前、术后第1天与术后第3天的尿微量白蛋白含量分别为0.89±0.24 mg/L、1.01±0.21 mg/L和0.90±0.31 mg/L;而对照组分别为0.91±0.13 mg/L、1.29±0.28 mg/L和1.26±0.32 mg/L,治疗组术后第1天与术后第3天的尿微量白蛋白含量明显低于对照组(P<0.05)。结论大剂量瑞舒伐他汀钙在冠脉造影患者中的应用能减少造影剂肾病的发生,对血尿素氮与肌酐水平都无明显影响,具有减轻肾脏损伤的作用,从而有效发挥肾组织保护作用。
Objective To investigate the renal tissue protective effects of rosuvastatin for the patients with coronary angiography. Methods From August 2012 to January 2015,120 patients with acute coronary syndrome were selected,and they were divided into the treatment group and the control group according to a random number table. Two groups performed angiography intervention and treatment group were given preoperative 3 d rosuvastatin（ 20 mg） intensive treatment before treatment,and the control group were received preoperative 3 d rosuvastatin（ 10 mg） intensive treatment. Results The incidence of contrast- induced nephropathy in treatment group was 1. 7%,and there was 10. 0% in the treatment group. The incidence of contrast- induced nephropathy in the treatment group was significantly lower than that of the control group（ P〈0. 05）.The preoperative serum creatinine and urea nitrogen compared were no significant difference（ P〉0. 05）,and the postoperative 1 d and 3 d creatinine and urea nitrogen in the treatment group were significantly lower than those of the control group（ P〈0. 05）. The difference was not statistically significant（ P〉0. 05）. The preoperative,postoperative 1 d and postoperative 3 d urinary albumin contents in the treatment group were0. 89 ± 0. 24 mg / L,1. 01 ± 0. 21 mg / L and 0. 90 ± 0. 31 mg / L; while the control group were 0. 91 ± 0. 13 mg / L,1. 29 ± 0. 28 mg / L and 1. 26 ±0. 32 mg / L,the postoperative 1d and postoperative 3 d urinary albumin contents in the treatment group were significantly lower than the control group（ P〈0. 05）. Conclusion Large dose rosuvastatin used in coronary angiography patients can reduce the incidence of contrast- induced nephropathy. It has no significant effect on blood urea nitrogen and creatinine levels,and can relieve kidney injury in order to effectively play a protective role in kidney tissue.
出处
《临床和实验医学杂志》
2016年第10期941-944,共4页
Journal of Clinical and Experimental Medicine
基金
河北省2014年度医学科学研究重点课题(ZD20140228)
关键词
急性冠脉综合征
冠脉造影
瑞舒伐他汀钙
肾组织
保护作用
Acute coronary syndrome
Coronary angiography
Rosuvastatin
Kidney tissue
Protective effect
作者简介
通讯作者：赵兴山，E—mail：13611022921@163．com
